Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H30N5O10P |
Molecular Weight | 519.4428 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C
InChI
InChIKey=JFVZFKDSXNQEJW-CQSZACIVSA-N
InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8452366https://www.ncbi.nlm.nih.gov/pubmed/20439609Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366https://www.ncbi.nlm.nih.gov/pubmed/20439609
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366http://adisinsight.springer.com/drugs/800020504
Curator's Comment: reference retrieved from http://www.sciencedirect.com/science/article/pii/S2211383512001402
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765248 |
58.0 µM [Kd] | ||
Target ID: HIV-1, subtype A 92RW009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.3 nM [EC50] | ||
Target ID: HIV-2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.5 nM [EC50] | ||
Target ID: HBV replication Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646420 |
0.49 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. | 1993 Feb |
|
Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. | 1998 Oct 16 |
|
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. | 2010 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: http://db.cbg-meb.nl/IB-teksten/h117062_fsuk.pdf
The recommended dose of Ictady (tenofovir disoproxil succinate) for the treatment of HIV or for the treatment of chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) exerts antiretrovirus activity in MT-4 cells infected with HIV-1 and HIV-2 with EC50 values of 5.9 and 4.9 uM, respectively
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ05AR09
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
STRIBILD (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR24
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR09
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR12
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AF07
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-VATC |
QJ05AR11
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR11
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-VATC |
QJ05AR06
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR06
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR08
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-VATC |
QJ05AR03
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-ATC |
J05AR03
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-VATC |
QJ05AF07
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
||
|
WHO-VATC |
QJ05AR08
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00300
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
2593
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
C418563
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
SUB20643
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
100000088017
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
Tenofovir disoproxil
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
5481350
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
DTXSID5052757
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
201341-05-1
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
m10559
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
F4YU4LON7I
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | |||
|
300195
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
63717
Created by
admin on Fri Dec 15 15:45:23 GMT 2023 , Edited by admin on Fri Dec 15 15:45:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD